The company reported net income of $121.4 million, or $4.25 per share, showing a sharp increase from the $90.3 million, or $3.10 per share, recorded during the same period last year. Revenue climbed 17% to reach $707.3 million, surpassing the $689.5 million consensus estimate from analysts polled by FactSet.
In section Market Quotes
Medpace Stock Climbs as Q2 Results Outpace Market Expectations
Investors pushed Medpace Holdings shares up 15% to $606.08 following a strong second-quarter performance that saw the clinical research firm comfortably outperforming Wall Street forecasts. This latest surge adds to a broader upward trend, marking an 8.1% gain for the company since the start of the year.
Looking ahead, Medpace issued bullish guidance for fiscal 2026. The firm projects annual revenue between $2.81 billion and $2.89 billion, with net income expected to land between $494 million and $514 million. These figures sit ahead of current analyst projections of $2.77 billion in revenue and $493.2 million in net income, reflecting sustained momentum for the research organization.
Comments (0)
No comments yet. Be the first!